Methotrexate Rheumatoid Arthritis Treatment Market Analysis and Forecast to 2023

DALLAS, March 18, 2015 /PRNewswire/ --

RnRMarketResearch.com adds "Methotrexate (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023" market research report provides detailed information on Methotrexate including product description, safety and efficacy profiles as well as a SWOT analysis.

Originally developed as a cancer therapy, Methotrexate has become the leading DMARD in most countries because of its rapid onset of action and low cost. MTX is an antineoplastic antimetabolite with immunosuppressant actions. Its use for the treatment of RA began in the 1970s, as it had been shown to sustain benefits for at least 50% of RA patients. Methotrexate is an antagonist of folic acid metabolism, and its effects in inflammatory diseases may be secondary to the induction of adenosine release and the inhibition of polyamines. Complete report is available at http://www.rnrmarketresearch.com/methotrexate-rheumatoid-arthritis-forecast-and-market-analysis-to-2023-market-report.html .

Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints. It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti-TNFs as extremely effective therapies for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars are approved and launch.

Scope 

• Overview of Rheumatoid Arthritis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
• Detailed information on Methotrexate including product description, safety and efficacy profiles as well as a SWOT analysis.
• Sales forecast for Methotrexate for the top 10 countries from 2013 to 2023.
• Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Australia, China and India.

Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=312801 . (This is a premium report priced at US$3495 for a single user License.)

Reasons to buy 

• Understand and capitalize by identifying products that are most likely to ensure a robust return.
• Stay ahead of the competition by understanding the changing competitive landscape for Rheumatoid Arthritis.
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
• Make more informed business decisions from insightful and in-depth analysis of Methotrexate performance.
• Obtain sales forecast for Methotrexate from 2013-2023 in top 10 countries (the US, France, Germany, Italy, Spain, the UK and Japan, Australia, China and India).

Explore more reports of Arthritis Drugs at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment/arthritis-drugs .

Related reports on Arthritis Drugs:

Humira (adalimumab) (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023 

Humira (adalimumab) is a recombinant, fully-human, IgG1 mAb that binds to TNFa and blocks its interaction with the p55 and p75 cell-surface receptors, which reduces inflammation and prevents tissue destruction. It was the first fully-humanized mAb TNF inhibitor to enter the market for the treatment of RA. Complete report available at http://www.rnrmarketresearch.com/humira-adalimumab-rheumatoid-arthritis-forecast-and-market-analysis-to-2023-market-report.html .

Remicade (infliximab) (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023 

Remicade (infliximab) was originally developed as a result of a collaboration between two professors at NYU Langone Medical Center and Centocor Ortho Biotech (acquired by Janssen Biotech, a subsidiary of J&J) (NYU Langone Medical Center, press release, August 12, 2005). It is first-generation TNF inhibitor consisting of a chimeric IgG1 mAb that is specific for TNFa. Remicade binds to TNFa with high affinity, neutralizing the effects of this cytokine, thus preventing synovial inflammation and decreasing joint erosion in patients with RA. Complete report available at http://www.rnrmarketresearch.com/remicade-infliximab-rheumatoid-arthritis-forecast-and-market-analysis-to-2023-market-report.html .

Biosimilars (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023 

With the cost of biologic therapies being very high, at an annual cost of at least $25,000, global healthcare systems need a reprieve from the expense. On September 9, 2013, Hospira's Inflectra and Celltrion's Remsima, which are both biosimilars of J&J's Remicade, were approved by the European Commission (EC) for marketing in the EU for multiple autoimmune diseases, including RA, Crohn's disease, ulcerative colitis, ankylosing spondylitis, and psoriatic arthritis. Remsima and Inflectra have been rolled out in selected European markets, although their launch in the 5EU is still pending due to potential intellectual property protections in these healthcare markets. The US-based generics company, Hospira, will market Inflectra in the EU, while the South Korean biotechnology company, Celltrion, the original developer of the infliximab biosimilar, will do so as well, but under the brand name Remsima, based on a collaboration forged between the two companies in 2009. Complete report available at http://www.rnrmarketresearch.com/biosimilars-rheumatoid-arthritis-forecast-and-market-analysis-to-2023-market-report.html .

Enbrel (etanercept) (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023 

Amgen's Enbrel (etanercept) is a soluble TNF inhibitor used for the treatment of moderate-to-severe active RA patients who are unresponsive to one or more csDMARDs. Enbrel is a leading biologic agent and is approved for multiple immunological indications, including psoriasis and ankylosing spondylitis. It is a fusion protein made by recombinant DNA technology, where the TNF receptor is combined with the Fc portion of human immunoglobulin G1 (IgG1). Enbrel binds to and neutralizes both lymphotoxin and TNFa, thus preventing synovial inflammation (DrugBank, 2012; Scott, 2012). Complete report available at http://www.rnrmarketresearch.com/enbrel-etanercept-rheumatoid-arthritis-forecast-and-market-analysis-to-2023-market-report.html .

About Us:
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact:
Ritesh Tiwari
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Tel:  +1-888-391-5441
[email protected]

SOURCE RnR Market Research